



August 25, 2009

Martin Dudziak, Ph.D.
Chief Science Officer
TETRADYN Corporation
28 Chase Gayton Circle, # 731
Henrico, VA 23238
martinjd@tetradyn.com

Dear Martin,

In addition to routine microbiology and virology testing services, the infectious diseases diagnostic laboratories at Vanderbilt University Medical Center (VUMC) conduct vigorous clinical and translational research programs that include development and validation of state-of-the-art molecular devices for detection and differentiation of diverse viral respiratory pathogens.

The CUBIT architecture and methodology developed by you and TETRADYN appear to offer much promise for bringing several innovative technologies to bear upon pressing problems in the medical and public health and battle against infectious diseases. The prospects of integrating into mobile platforms a combination of early warning, basic detection, and rapid sequence identification at the strain level would offer highly valuable benefits in our time of increased risks. As a poignant example, the CUBIT platform would support the early identification of mutations that could alert health authorities to the rise of a new and more lethal form of novel H1N1 influenza.

We are interested in collaborative efforts with you and the TETRADYN team, understanding that such could take many traditional forms of research, testing, validation, and cooperation. We could consider, for instance, a phased project whereby new RT-PCR assays and instrumentation are introduced as part of a validation program using clinical specimens originating within VUMC or acquired through TETRADYN or public health labs. We would expect TETRADYN to provide all necessary equipment, supplies (including reagents and specialized labware and/or electronics), training and maintenance, and a co-presence of technical staff such as would be appropriate to the research and clinical dimensions of the project.


We understand the general concept of the CRAIDO (Community RAPid Response to Infectious Disease Outbreaks) network of labstations, including mobile lab units for which a Pilot lab station is being designed and assembled by TETRADYN in response to various initiatives for H1N1 pandemic readiness. As board-certified clinical microbiologists possessing expertise in diagnostic molecular microbiology and virology, we will provide advice in the design of protocols that will most accurately and efficiently field test CRAIDO performance and potential. We are able to provide a place for this labstation in the form of a suitable laboratory room and/or outdoor parking for its operation and demonstration, under the umbrella of collaborative teaming that would involve appropriate funding and intellectual property provisions. We will help you modify and optimize the operating protocol using a panel of well-characterized clinical specimens. We are also interested to explore involvement in the VSRB (Virtual Sample Bank Repository), and in the near future, organize and participate in a multi-center clinical validation study.

We are looking forward to working with you on this very important and interesting project.

Sincerely yours,



Yi-Wei Tang, M.D., Ph.D.
Associate Professor of Pathology and Medicine
Director, Molecular Infectious Diseases Laboratory



James Chappell, M.D., Ph.D.
Assistant Professor of Pathology and Pediatrics
Director, Clinical Virology Laboratory